Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

3,437 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Subsequent primary malignancies among multiple myeloma patients treated with or without lenalidomide.
Rollison DE, Komrokji R, Lee JH, Hampras S, Fulp W, Fisher K, Baz R, Nishihori T, Xu Q, Olesnyckyj M, Kenvin L, Knight R, Sullivan D, Alsina M, Dalton W, Shain KH. Rollison DE, et al. Among authors: knight r. Leuk Lymphoma. 2017 Mar;58(3):560-568. doi: 10.1080/10428194.2016.1207763. Epub 2016 Jul 18. Leuk Lymphoma. 2017. PMID: 27424609 Free PMC article.
Lenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-Analysis.
McCarthy PL, Holstein SA, Petrucci MT, Richardson PG, Hulin C, Tosi P, Bringhen S, Musto P, Anderson KC, Caillot D, Gay F, Moreau P, Marit G, Jung SH, Yu Z, Winograd B, Knight RD, Palumbo A, Attal M. McCarthy PL, et al. J Clin Oncol. 2017 Oct 10;35(29):3279-3289. doi: 10.1200/JCO.2017.72.6679. Epub 2017 Jul 25. J Clin Oncol. 2017. PMID: 28742454 Free PMC article.
Subsequent primary malignancies and acute myelogenous leukemia transformation among myelodysplastic syndrome patients treated with or without lenalidomide.
Rollison DE, Shain KH, Lee JH, Hampras SS, Fulp W, Fisher K, Al Ali NH, Padron E, Lancet J, Xu Q, Olesnyckyj M, Kenvin L, Knight R, Dalton W, List A, Komrokji RS. Rollison DE, et al. Among authors: knight r. Cancer Med. 2016 Jul;5(7):1694-701. doi: 10.1002/cam4.721. Epub 2016 Apr 20. Cancer Med. 2016. PMID: 27098006 Free PMC article.
Health-related quality of life outcomes of lenalidomide in transfusion-dependent patients with Low- or Intermediate-1-risk myelodysplastic syndromes with a chromosome 5q deletion: results from a randomized clinical trial.
Revicki DA, Brandenburg NA, Muus P, Yu R, Knight R, Fenaux P. Revicki DA, et al. Among authors: knight r. Leuk Res. 2013 Mar;37(3):259-65. doi: 10.1016/j.leukres.2012.11.017. Epub 2012 Dec 27. Leuk Res. 2013. PMID: 23273538 Clinical Trial.
Connect MM® - the Multiple Myeloma Disease Registry: incidence of second primary malignancies in patients treated with lenalidomide.
Rifkin RM, Abonour R, Shah JJ, Mehta J, Narang M, Terebelo H, Gasparetto C, Toomey K, Hardin JW, Lu JJ, Kenvin L, Srinivasan S, Knight R, Nagarwala Y, Durie BG. Rifkin RM, et al. Among authors: knight r. Leuk Lymphoma. 2016 Sep;57(9):2228-31. doi: 10.3109/10428194.2015.1132419. Epub 2016 Jan 13. Leuk Lymphoma. 2016. PMID: 26766599 No abstract available.
3,437 results